Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
EGHT 8x8 Inc
REGI Renewable Energy Group Inc
MCK Mckesson Corp
CNBX Cannabics Pharmaceuticals Inc
BLK BlackRock Inc
FNMA Federal National Mortgage Association
MPW Medical Properties Trust Inc
PSXP Phillips 66 Partners LP
EQ Equillium Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$58.15
Day's Change
-0.38 (-0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
58.58
Day's Low
57.18
Volume
(Average)
Volume:
11,871,686

10-day average volume:
12,568,205
11,871,686

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout

1:59 pm ET September 14, 2020 (Globe Newswire) Print

Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. ("Immunomedics") (NASDAQ GS: IMMU) regarding possible breaches of fiduciary duties and other violations of law related to Immunomedics' agreement to be acquired by Gilead Sciences, Inc. ("Gilead") (NASDAQ GS: GILD). Under the terms of the agreement, Immunomedics' shareholders will receive $88.00 per share in cash.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-immunomedics-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com.

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.

Seth D. Rigrodsky

Gina M. Serra

(888) 969-4242 (Toll Free)

(302) 295-5310

Fax: (302) 654-7530

info@rl-legal.com

https://rl-legal.com

https://ml.globenewswire.com/media/d13992b2-5f49-41b3-a558-97131afbfcda/small/pdf-to-png-logo-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.